Cargando…

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent a recognized option for the treatment of patients affected by indolent B cell lymphomas. However, small molecules as single agents show limited success in their ability in inducing complete responses, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guidetti, Francesca, Arribas, Alberto J., Sartori, Giulio, Spriano, Filippo, Barnabei, Laura, Tarantelli, Chiara, Von Roemeling, Reinhard, Martinez, Elizabeth, Zucca, Emanuele, Bertoni, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864368/ https://www.ncbi.nlm.nih.gov/pubmed/36675328 http://dx.doi.org/10.3390/jcm12020399

Ejemplares similares

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023)

P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA
por: Von Roemeling, C., et al.
Publicado: (2022)

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022)

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
por: Tarantelli, Chiara, et al.
Publicado: (2019)

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
por: Gaudio, Eugenio, et al.
Publicado: (2020)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
por: Hicks, Stuart W., et al.
Publicado: (2019)

Recent advances in understanding the biology of marginal zone lymphoma
por: Bertoni, Francesco, et al.
Publicado: (2018)

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
por: Napoli, Sara, et al.
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
por: Von Roemeling, Christina A., et al.
Publicado: (2023)

Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
por: Priebe, Valdemar, et al.
Publicado: (2020)

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma
por: Sartori, Giulio, et al.
Publicado: (2021)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Irak : cinco años después /
por: Rosas, María Cristina
Publicado: (2008)

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
por: Tarantelli, Chiara, et al.
Publicado: (2021)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma
por: Vann, Kendra R., et al.
Publicado: (2022)

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
por: Bennett, Joshua, et al.
Publicado: (2022)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Outgrowing IRAK-4
por: Bashyam, Hema
Publicado: (2007)

IRAK signalling in cancer
por: Rhyasen, G W, et al.
Publicado: (2015)

IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
por: Johnson, Zoë, et al.
Publicado: (2023)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023)

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma
por: Yuan, Hongwei, et al.
Publicado: (2022)

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
por: Mensah, Afua A., et al.
Publicado: (2018)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
por: Kong, Weibo, et al.
Publicado: (2021)

IRAK-4 Inhibitors for Inflammation
por: Wang, Zhulun, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_leqvk3e85an89v717div6e1spd